May 17, 2020

Mark Clein, Co-Founder and CEO of Precision Medicine Group, delivers the keynote address for BioTrinity 2020

You can view his address at your convenience here. In the course of his presentation you will hear: The ways in which digital technology is transforming patient care and impacting clinical trials What new breakthroughs are on the horizon How precision medicine continues to advance and affect patient treatment and […]
May 16, 2020

World Preclinical Congress “Cancer Immunotherapy and Combinations

Thomas Kleen, PhD, Exec. VP Immune Monitoring, Epiontis, spoke at the World Preclinical Congress “Cancer Immunotherapy and Combinations”.
May 16, 2020

Next Generation Diagnostics Summit 2017

Thomas Kleen, PhD, Exec. VP Immune Monitoring, Epiontis, spoke at the Next Generation Diagnostics Summit 2017.
May 16, 2020

ESMO 2017 Congress

Thomas Kleen, PhD, Exec. VP Immune Monitoring, Epiontis, attended the ESMO 2017 Congress.
May 16, 2020

18th Meeting of the European Society for Immunodeficiencies (ESID 2017)

Christoph Sachsenmaier, PhD, VP Strategic Business Development, Epiontis, attended the 18th Meeting of the European Society for Immunodeficiencies (ESID 2017).
May 16, 2020

6th Cancer Therapeutics & Partnering Summit

Thomas Kleen, PhD, Exec. VP Immune Monitoring, Epiontis, spoke at the 6th Cancer Therapeutics & Partnering Summit by GTCbio.
May 16, 2020

Novel Cancer Therapeutics Summit

May 16, 2020

6th ImmunoTX Summit

Ulrich Hoffmüller, PhD, MBA, VP, Immune Monitoring Solutions and Thomas Kleen, PhD, Exec. VP Immune Monitoring, attended the 6th ImmunoTX Summit by GTCbio
May 16, 2020

11th Biomarker Summit 2018

Thomas Kleen, PhD, VP, Immune Monitoring and Specialty Lab Solutions, spoke at the 11th Biomarker Summit 2018 by GTCbio